GLS-010 + bevacizumab

**GLS-010 + bevacizumab** is an investigational combination therapy consisting of zimberelimab (GLS-010), a fully human anti-PD-1 IgG4 monoclonal antibody, and bevacizumab, an anti-VEGF humanized monoclonal antibody. Zimberelimab blocks PD-1, restoring T cell activity and promoting anti-tumor immune responses, while bevacizumab binds vascular endothelial growth factor (VEGF), inhibiting angiogenesis. The combination is being investigated as a first-line treatment for persistent, recurrent, or metastatic cervical cancer, aiming to exploit synergistic effects between immune checkpoint blockade and anti-angiogenic therapy[2][3].

Brand names

zimberelimabAvastin

Other names

zimberelimab + bevacizumab